Drug Research
AstraZeneca and Neurimmune sign exclusive global collaboration and licence agreement to develop and commercialise NI006
Alexion, AstraZeneca’s Rare Disease group, has entered into an exclusive global collaboration and licence agreement with Neurimmune AG for NI006, an investigational human monoclonal antibody...
Drug Research
In-Vitro Biology Capabilities Expanded By Piramal Pharma
Piramal Pharma Solutions has confirmed that it has put in a multi-million dollar investment to create a top-notch screening facility that will elevate the in-vitro...
Drug Research
Ascletis expands production of ritonavir oral tablets & oral direct-acting antiviral R&D pipeline to treat SARS-CoV-2 infection
Ascletis Pharma Inc. announces the expansion of the production of ritonavir oral tablets and oral direct-acting antiviral R&D pipeline for the treatment of SARS-CoV-2 infection....
Drug Research
Amyris and Immunitybio Complete Joint Venture for Next Generation Covid-19 RNA Vaccine
Amyris, Inc., a leading synthetic biotechnology company accelerating the world to sustainable consumption through its Lab-to-Market operating platform, and ImmunityBio, a clinical-stage immunotherapy company, today...
Drug Research
REGENXBIO Announces Orphan Drug Designation Granted to RGX-202, a Novel Gene Therapy Candidate for the Treatment of Duchenne Muscular Dystrophy
REGENXBIO Inc. announced the U.S. FDA granted Orphan Drug Designation for RGX-202, a potential one-time gene therapy for the treatment of Duchenne muscular dystrophy (Duchenne)....
Drug Research
Chiesi Group focuses on biological drugs: an investment of 85 million euros for an international centre of excellence in Parma
Chiesi, the international research-focused pharmaceuticals and healthcare Group (Chiesi Group), presented today to the Italian Minister of Economic Development Giancarlo Giorgetti in Rome, the Biotech...
Drug Research
ViiV Healthcare announces US FDA approval of Apretude, the first and only long-acting injectable option for HIV prevention
ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (GSK), with Pfizer Inc. (Pfizer) and Shionogi Limited (Shionogi) as shareholders, announced that...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.